US equities
|
INTC
$119.13
▼-0.17%
MU
$1,074.89
▲+0.00%
NVDA
$233.95
▲+0.00%
SNDK
$1,719.99
▲+0.00%
SDEV
$7.48
▲+0.00%
SPCX
$158.96
▲+0.00%
AMD
$633.91
▲+0.00%
TSLA
$370.59
▲+0.00%
INTC
$119.13
▼-0.17%
MU
$1,074.89
▲+0.00%
NVDA
$233.95
▲+0.00%
SNDK
$1,719.99
▲+0.00%
SDEV
$7.48
▲+0.00%
SPCX
$158.96
▲+0.00%
AMD
$633.91
▲+0.00%
TSLA
$370.59
▲+0.00%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
OS Therapies Incorporated Common Stock
(NY:
OSTX
)
1.620
UNCHANGED
Delayed Quote
Updated: 8:00 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about OS Therapies Incorporated Common Stock
< Previous
1
2
3
4
5
Next >
Rosen Law Firm Encourages OS Therapies Incorporated Investors to Inquire About Securities Class Action Investigation – OSTX
April 10, 2026
From
The Rosen Law Firm, P.A.
Via
Business Wire
OS Therapies Appoints Craig Eagle, MD as Strategic Advisor
April 08, 2026
Senior leadership roles at Guardant Health, Genentech and PfizerRegulatory, clinical and commercial expertise in therapeutics and biomarkersWill assist with osteosarcoma...
Via
Newsfile
OS Therapies Completes $5.25M Registered Direct Offering Primarily with Pre-Existing High-Net-Worth Investors
April 02, 2026
Company expects approximately $2 million in non-dilutive VAT refunds from wholly owned U.K. subsidiary in 2Q-26Company expects to receive approximately...
Via
Newsfile
OS Therapies Completes Submission of Biomarker & Clinical Data for U.S. FDA Pre-BLA Meeting, Reports Full Year 2025 Financial Results and Provides Business Update
March 31, 2026
December 2025 Type C Meeting confirmed immune biomarkers suitability to establish surrogate clinical efficacy that could support BLA under Accelerated...
Via
Newsfile
OS Therapies Granted Meetings with U.S. FDA, U.K. MHRA, EMA and Australian Therapeutic Goods Administration to Review Global Confirmatory Phase 3 Trial for OST-HER2 in Metastatic Osteosarcoma
March 27, 2026
Meetings with all four regulatory agencies scheduled to occur in the second quarter of 2026, with expected Phase 3 commencement...
Via
Newsfile
OS Therapies Granted EMA's Advanced Therapy Medicinal Product (ATMP) Designation for OST-HER2 in the Treatment of Pulmonary Recurrence in Resected Osteosarcoma
March 25, 2026
ATMP benefits include access to the Conditional Marketing Authorisation accelerated market access pathway in Europe, significantly reduced user fees for...
Via
Newsfile
Get insights into the top gainers and losers of Thursday's after-hours session.
↗
March 19, 2026
Via
Chartmill
OS Therapies Announces FDA OST-HER2 Type D Meeting Elevated to Type B Pre-BLA Meeting
March 09, 2026
FDA's elevated meeting status signals transition from biomarker data discussions to Accelerated Approval discussionsOS Therapies on track to complete clinical...
Via
Newsfile
Topics
Intellectual Property
OS Therapies Provides Global Regulatory Update for OST-HER2 in Recurrent, Fully Resected, Pulmonary Metstatic Osteosarcoma
↗
February 17, 2026
Additional forthcoming biomarker data from human trial expected to further characterize immune pathway activation and its relationship to clinical outcomesU.S.,...
Via
Newsfile
OS Therapies Applauds Reauthorization of Pediatric Priority Review Voucher Program to Advance Breakthrough Osteosarcoma Immunotherapies
February 04, 2026
New York, New York--(Newsfile Corp. - February 4, 2026) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or...
Via
Newsfile
OS Therapies Initiates US FDA BLA Filing for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
February 02, 2026
Request for FDA Rolling Review submitted to FDA on January 30, 2026Non-Clinical and CMC BLA modules submitted to FDAAt FDA's...
Via
Newsfile
OS Therapies Announces Positive Biomarker Data from Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
January 15, 2026
Activation of immune blood biomarkers from interferon gamma pathway distinguished long term survivors (>=2 years) from short-term survivors (<1year)Pre-specified pathway...
Via
Newsfile
OS Therapies Announces Filing Form S-1 of OS Animal Health Subsidiary
January 14, 2026
OS Animal Health (OSAH), a wholly-owned subsidiary of OS Therapies (OSTX), targeting Initial Public Offering (IPO) on NYSE American or...
Via
Newsfile
OS Therapies Enters into Warrant Inducement Agreements
January 12, 2026
$7.53M gross proceeds raised from pre-existing investors, providing capital runway into 2027All nine investors that were offered agreed to participateNet...
Via
Newsfile
OS Therapies Provides First Half 2026 Corporate Outlook
January 05, 2026
Company finalizing preparations for end of January 2026 U.S. FDA Biologics License Application (BLA) submission for OST-HER2 program in the...
Via
Newsfile
Topics
Regulatory Compliance
Market Signals Highlight Next Wave of Immunotherapy Growth (OSTX, IBRX)
December 16, 2025
Via
AB Newswire
OS Therapies Announces Successful Type C Meeting with US FDA Regarding Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
December 15, 2025
FDA confirmed that data from single-arm studies in rare diseases, such as in ultra-rare deadly pediatric cancer osteosarcoma, could support...
Via
Newsfile
OS Therapies Announces Successful pre-Marketing Authorisation Application Meeting with UK MHRA Regarding the Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
December 09, 2025
Alignment achieved on all key points surrounding non-clinical, CMC and post-market authorization confirmatory study designBiomarker data advanced as key pre-specified...
Via
Newsfile
OS Therapies Announces FDA PDUFA Waiver & EMA Grants Union Marketing Authorisation Eligibility
December 05, 2025
U.S. FDA grants waiver of application fee for BLA Filing of OST-HER2Scheduled pre-Marketing Authorisation Application meeting with United Kingdom's Medicines...
Via
Newsfile
OS Therapies Receives Non-Proprietary Name 'daznelimgene lisbac' for OST-HER2 from World Health Organization
November 25, 2025
New York, New York--(Newsfile Corp. - November 25, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the...
Via
Newsfile
Stonegate Capital Partners Updates Coverage on OS Therapies Inc. (OSTX) 3Q25
November 21, 2025
Dallas, Texas--(Newsfile Corp. - November 21, 2025) - OS Therapies Inc. (NYSE American: OSTX): Stonegate Capital Partners updates their coverage...
Via
Newsfile
OS Therapies to Spinoff OS Animal Health into Standalone Public Company
November 20, 2025
Successful preliminary discussion with NYSE representatives and potential investorsOS Therapies shareholders to receive direct equity participation in new listing'Shelter Me:...
Via
Newsfile
OS Therapies Reports Third Quarter 2025 Financial Results and Provides Business Update
November 17, 2025
Type C Meeting with US FDA set for December 11, 2025 to address key items following August 27, 2025 End...
Via
Newsfile
Why Quantum Computing Shares Are Trading Higher By Over 23%; Here Are 20 Stocks Moving Premarket
↗
November 17, 2025
Via
Benzinga
OS Therapies Announces Overall and Event Free Survival Key Subgroup Data for OST-HER2 in Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
October 22, 2025
New York, New York--(Newsfile Corp. - October 22, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the...
Via
Newsfile
OS Therapies Granted Final Type C Meeting by U.S. FDA and pre-MAA Meeting by U.K. MHRA for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
October 17, 2025
Final FDA Type C Meeting December 11, 2025 - biomarker data to be availableOctober 10, 2025 FDA/Osteosarcoma Institute Workshop narrows...
Via
Newsfile
OS Therapies Reports Strong 2-Year Survival Data For Bone Cancer Immunotherapy Candidate
↗
October 10, 2025
OS Therapies reports 75% two-year survival in osteosarcoma trial, plans regulatory filings with the FDA, EMA, and MHRA following positive Phase 2b results.
Via
Benzinga
OS Therapies Announces Statistically Significant Positive Final 2-Year Overall Survival Data from Phase 2b Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully-Resected, Pulmonary Metastatic Osteosarcoma
October 10, 2025
75% of OST-HER2 treated patients achieved 2-year overall survival compared with 40% in the historical control group (p < 0.0001)100%...
Via
Newsfile
OS Therapies Provides Positive EMA Regulatory Update Following Positive Rapporteur Meeting
October 09, 2025
Overall survival recognized as key efficacy endpoint in osteosarcoma, where no standard of care existsRapporteur highlights potential broader benefits of...
Via
Newsfile
OS Therapies to Participate in Fall 2025 Conferences and Events
October 07, 2025
Daytime Emmy Awards participation - 2 nomination for 'Shelter Me: Cancer Pioneers' Comparative Oncology documentary that features clinicians, veterinarians and...
Via
Newsfile
< Previous
1
2
3
4
5
Next >
